Dobutamine Versus Vasopressin After Mesenteric Ischemia

Area of Science:

• Gastroenterology
• Pharmacology
• Microcirculation Research

Background:

• Gastrointestinal blood flow can be compromised during vasopressor therapy.
• Endothelin expression may contribute to microcirculatory dysfunction.
• Mesenteric ischemia can lead to significant gastrointestinal injury.

Purpose of the Study:

• To investigate the effects of vasopressin and dobutamine on gastrointestinal mucosal microcirculation post-mesenteric ischemia.
• To analyze endothelin expression and morphologic injury in response to these vasopressors.
• To evaluate the impact on tissue blood flow and inflammatory markers.

Main Methods:

• A pig model of mesenteric ischemia was used, with groups receiving vehicle, dobutamine, or vasopressin.
• Measurements included gastric, jejunal, and rectosigmoidal mucosal blood flow.
• Endothelin-1 (ET-1) expression, receptor subtypes, mucosal injury, and inflammatory cell infiltration were assessed.

Main Results:

• Mesenteric ischemia increased jejunal ET-1 expression and mucosal injury.
• Dobutamine worsened jejunal perfusion, increased ET-1 expression, and promoted leukocytic infiltration.
• Vasopressin enhanced postischemic blood flow and capillary density with reduced ET-1 expression and no leukocytic infiltration.

Conclusions:

• Vasopressin effectively mitigates mesenteric ischemia-induced microcirculatory and tissue integrity damage.
• Dobutamine does not offer similar protective effects and may exacerbate injury.
• Findings suggest vasopressin as a potential therapeutic agent for post-ischemic gastrointestinal complications.